Evidence-based Pre-exposure: PrEP and your patients

HIV prevention is crucial to ending the HIV pandemic. Learn more about the benefits and limitations of currently available pre-exposure prophylaxis drugs and influencing factors that determine best choice of prevention method(s) for each patient.

Learning objectives:

  • To provide motivation to clinicians to treat the last 2 million HIV-positive patients and put them on effective treatment
  • To extend PrEP coverage with oral medication, vaginal ring and long-acting injectables
  • To promote the use of specially trained community pharmacists to extend grassroots coverage
  • To treat patients effectively with Triple Therapy (ART) as a prelude to PrEP
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.

To access this module, please register or login: